APA (7th ed.) Citation

Taskinen, M., Del Prato, S., Bujas-Bobanovic, M., Louie, M. J., Letierce, A., Thompson, D., & Colhoun, H. M. (2018). Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis (00219150), 276, 124. https://doi.org/10.1016/j.atherosclerosis.2018.07.017

Chicago Style (17th ed.) Citation

Taskinen, Marja-Riitta, Stefano Del Prato, Maja Bujas-Bobanovic, Michael J. Louie, Alexia Letierce, Desmond Thompson, and Helen M. Colhoun. "Efficacy and Safety of Alirocumab in Individuals with Type 2 Diabetes Mellitus with or Without Mixed Dyslipidaemia: Analysis of the ODYSSEY LONG TERM Trial." Atherosclerosis (00219150) 276 (2018): 124. https://doi.org/10.1016/j.atherosclerosis.2018.07.017.

MLA (9th ed.) Citation

Taskinen, Marja-Riitta, et al. "Efficacy and Safety of Alirocumab in Individuals with Type 2 Diabetes Mellitus with or Without Mixed Dyslipidaemia: Analysis of the ODYSSEY LONG TERM Trial." Atherosclerosis (00219150), vol. 276, 2018, p. 124, https://doi.org/10.1016/j.atherosclerosis.2018.07.017.